JP5753179B2 - シクロヘキサン誘導体化合物 - Google Patents

シクロヘキサン誘導体化合物 Download PDF

Info

Publication number
JP5753179B2
JP5753179B2 JP2012536427A JP2012536427A JP5753179B2 JP 5753179 B2 JP5753179 B2 JP 5753179B2 JP 2012536427 A JP2012536427 A JP 2012536427A JP 2012536427 A JP2012536427 A JP 2012536427A JP 5753179 B2 JP5753179 B2 JP 5753179B2
Authority
JP
Japan
Prior art keywords
group
methyl
phenyl
trans
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012536427A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012043445A1 (ja
Inventor
戸田　成洋
成洋 戸田
理恵子 高野
理恵子 高野
健 志田
健 志田
隆廣 片桐
隆廣 片桐
充広 岩本
充広 岩本
真二 蘆田
真二 蘆田
真美 山崎
真美 山崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2012536427A priority Critical patent/JP5753179B2/ja
Publication of JPWO2012043445A1 publication Critical patent/JPWO2012043445A1/ja
Application granted granted Critical
Publication of JP5753179B2 publication Critical patent/JP5753179B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012536427A 2010-09-27 2011-09-26 シクロヘキサン誘導体化合物 Expired - Fee Related JP5753179B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012536427A JP5753179B2 (ja) 2010-09-27 2011-09-26 シクロヘキサン誘導体化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010215403 2010-09-27
JP2010215403 2010-09-27
PCT/JP2011/071830 WO2012043445A1 (ja) 2010-09-27 2011-09-26 シクロヘキサン誘導体化合物
JP2012536427A JP5753179B2 (ja) 2010-09-27 2011-09-26 シクロヘキサン誘導体化合物

Publications (2)

Publication Number Publication Date
JPWO2012043445A1 JPWO2012043445A1 (ja) 2014-02-06
JP5753179B2 true JP5753179B2 (ja) 2015-07-22

Family

ID=45892891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012536427A Expired - Fee Related JP5753179B2 (ja) 2010-09-27 2011-09-26 シクロヘキサン誘導体化合物

Country Status (29)

Country Link
US (3) US8710060B2 (enExample)
EP (1) EP2623492B1 (enExample)
JP (1) JP5753179B2 (enExample)
KR (1) KR20130109124A (enExample)
CN (1) CN103108866B (enExample)
AU (1) AU2011309212B2 (enExample)
BR (1) BR112013007145A2 (enExample)
CA (1) CA2812898C (enExample)
CO (1) CO6690804A2 (enExample)
CY (1) CY1115450T1 (enExample)
DK (1) DK2623492T3 (enExample)
ES (1) ES2478518T3 (enExample)
HR (1) HRP20140720T1 (enExample)
IL (1) IL225440A (enExample)
IN (1) IN2013MN00506A (enExample)
MX (1) MX2013003219A (enExample)
MY (1) MY157542A (enExample)
NZ (1) NZ609596A (enExample)
PH (1) PH12013500583A1 (enExample)
PL (1) PL2623492T3 (enExample)
PT (1) PT2623492E (enExample)
RS (1) RS53447B (enExample)
RU (1) RU2013119603A (enExample)
SG (1) SG188415A1 (enExample)
SI (1) SI2623492T1 (enExample)
SM (1) SMT201400109B (enExample)
TW (1) TWI501953B (enExample)
WO (1) WO2012043445A1 (enExample)
ZA (1) ZA201301652B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012043445A1 (ja) * 2010-09-27 2012-04-05 第一三共株式会社 シクロヘキサン誘導体化合物
US10973439B2 (en) 2016-12-29 2021-04-13 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis, and feedback
US9773330B1 (en) 2016-12-29 2017-09-26 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis, and feedback
US10352962B2 (en) 2016-12-29 2019-07-16 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis and feedback
US11318350B2 (en) 2016-12-29 2022-05-03 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis, and feedback

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085694A2 (en) * 2000-05-05 2001-11-15 Ortho-Mcneil Pharmaceutical, Inc. Substituted diamide derivatives useful as motilin antagonists
WO2005027637A1 (en) * 2003-09-17 2005-03-31 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
WO2007144400A1 (en) * 2006-06-15 2007-12-21 Glaxo Group Limited Benzylpiperazine derivatives as motilin receptor antagonists
WO2008000729A1 (en) * 2006-06-28 2008-01-03 Glaxo Group Limited Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
WO2009068552A1 (en) * 2007-11-28 2009-06-04 Glaxo Group Limited Piperazinyl-sulfonamide derivatives useful in the treatment of gpr38 receptor mediated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515381D0 (en) * 2005-07-26 2005-08-31 Glaxo Group Ltd Compounds
GB0612844D0 (en) * 2006-06-28 2006-08-09 Glaxo Group Ltd Compounds
WO2012043445A1 (ja) * 2010-09-27 2012-04-05 第一三共株式会社 シクロヘキサン誘導体化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085694A2 (en) * 2000-05-05 2001-11-15 Ortho-Mcneil Pharmaceutical, Inc. Substituted diamide derivatives useful as motilin antagonists
WO2005027637A1 (en) * 2003-09-17 2005-03-31 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
WO2007144400A1 (en) * 2006-06-15 2007-12-21 Glaxo Group Limited Benzylpiperazine derivatives as motilin receptor antagonists
WO2008000729A1 (en) * 2006-06-28 2008-01-03 Glaxo Group Limited Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
WO2009068552A1 (en) * 2007-11-28 2009-06-04 Glaxo Group Limited Piperazinyl-sulfonamide derivatives useful in the treatment of gpr38 receptor mediated diseases

Also Published As

Publication number Publication date
HK1185081A1 (en) 2014-02-07
AU2011309212B2 (en) 2014-06-19
EP2623492A4 (en) 2013-09-25
CN103108866A (zh) 2013-05-15
EP2623492A1 (en) 2013-08-07
US20130289048A1 (en) 2013-10-31
ES2478518T3 (es) 2014-07-22
US20140221391A1 (en) 2014-08-07
US20140221392A1 (en) 2014-08-07
US8710060B2 (en) 2014-04-29
CO6690804A2 (es) 2013-06-17
BR112013007145A2 (pt) 2016-06-14
SMT201400109B (it) 2014-09-08
MX2013003219A (es) 2013-06-18
EP2623492B1 (en) 2014-05-14
CA2812898A1 (en) 2012-04-05
US9051255B2 (en) 2015-06-09
AU2011309212A1 (en) 2013-03-21
CY1115450T1 (el) 2017-01-04
PT2623492E (pt) 2014-08-29
RU2013119603A (ru) 2014-11-10
TWI501953B (zh) 2015-10-01
MY157542A (en) 2016-06-15
NZ609596A (en) 2013-12-20
PL2623492T3 (pl) 2014-09-30
IL225440A0 (en) 2013-06-27
IL225440A (en) 2015-11-30
JPWO2012043445A1 (ja) 2014-02-06
SI2623492T1 (sl) 2014-09-30
HRP20140720T1 (hr) 2014-08-29
RS53447B (sr) 2014-12-31
IN2013MN00506A (enExample) 2015-05-29
TW201217342A (en) 2012-05-01
ZA201301652B (en) 2014-04-30
CN103108866B (zh) 2015-09-09
DK2623492T3 (da) 2014-08-11
SG188415A1 (en) 2013-04-30
KR20130109124A (ko) 2013-10-07
CA2812898C (en) 2015-11-17
PH12013500583A1 (en) 2013-05-20
WO2012043445A1 (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
TWI839461B (zh) Il-17a調節物及其用途
JP5425772B2 (ja) カルボン酸化合物
ES2525820T3 (es) Derivados del ácido hidroxámico N-enlazados útiles como agentes antibacterianos
US20230094305A1 (en) Human plasma kallikrein inhibitors
DE60107820T2 (de) Neue verwendung von phenylheteroalkylamin-derivaten
JP6301842B2 (ja) 複素環アミド誘導体及びそれを含有する医薬
JP5753179B2 (ja) シクロヘキサン誘導体化合物
KR20190077544A (ko) Magl 억제제
DE10100772A1 (de) Ether- und Amidverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antidiabetika
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
JP2013147443A (ja) β置換カルボン酸誘導体
HK1185081B (en) Cyclohexane derivative compound
JP2011148774A (ja) カルボン酸化合物を含有する医薬
JP2012067054A (ja) スルホンアミド誘導体化合物
JP2025539698A (ja) 新規シアノピリジンｋｈｋ阻害剤化合物
US20250346567A1 (en) Substituted pyridine and phenyl compounds
TWI682928B (zh) 達比加群烷酯衍生物及其製備方法和在藥學上的用途
JP2005519951A (ja) β３アドレナリン性受容体作動薬としてのアミノアルコール誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140813

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150128

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150521

R150 Certificate of patent or registration of utility model

Ref document number: 5753179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees